Combined Effects of Aerobic Exercise and Strength Training Among Post CABG Patients

July 17, 2026 updated by: Riphah International University

Combined Effects of Aerobic Exercise and Strength Training on Functional Capacity, Cardiorespiratory Fitness and Quality of Life With Cardiac Rehabilitation Phase II Among Post CABG Patients

Title of study Combined effects aerobic exercise and strength training on functional capacity, cardiorespiratory fitness and quality of life with cardiac rehabilitation phase II among post CABG patients Objective (s) of the study To investigate the combined effects of aerobic exercise and strength training on functional capacity, cardiorespiratory fitness and quality of life with cardiac rehabilitation phase II among post CABG patients.

Methodology (Design, sample size, sampling technique, Study setting, inclusion and exclusion criteria and Tool) Design: Randomized Controlled Trial Sample Size: 42 patients Sampling Technique: Convenient sampling technique will be used for selection of patient after that simple random sampling technique will be used for randomization among groups Study Setting: Hospital Setting SF-12, 6-min walk test, VO2 max, step test This study will not harm any fundamental rights of the patients and will consider and respect the preferences of patients.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Coronary artery bypass grafting (CABG) is a common surgical procedure for coronary artery disease (CAD). Post-CABG patients often experience decreased functional capacity, muscle strength, and quality of life due to prolonged bed rest, surgical trauma, and underlying cardiovascular disease. Cardiac Rehabilitation after coronary artery bypass graft surgery is necessary to prevent complications, improve functioning, and alleviate symptoms. Aerobic exercises and strength training are used in CR, but their combined effects on post-CABG patients are not well understood. The objective of this study will be to investigate the combined effects of aerobic exercise and strength training on functional capacity, cardiorespiratory fitness and quality of life with cardiac rehabilitation phase II among post CABG patients.

Study design will be randomized controlled trial. 42 patients will be included in study. Data will be collected from Imran Idrees hospital, Sialkot. Convenient sampling technique will be used for selection of patient after that simple random sampling technique for randomization among groups. Study will be conducted within 10 months after approval of synopsis. The SF-12 questionnaire will be used for quality of life, 6-minute walk test for functional capacity, step test and VO2max for cardiorespiratory fitness. Both genders aged between 30 to 60 years with stable cardiovascular condition and no other comorbidities will be included in this study. Participants with any musculoskeletal or neurological impairment and symptoms of significant myocardial ischemia, including chest pain and any history of fracture or surgery will be excluded from this study. Patients will be divided in to two groups. Group A will be assigned aerobic exercise and Group B will be assigned aerobic exercise and strength training. Pre and post values for functional capacity, cardiorespiratory fitness and quality of life will be recorded. Data will be analyzed by using SPSS version 24. After testing the Normality of data by applying Shapiro-wilk test, paired sample t-test/ independent t-test / Anova test to find which technique will be more beneficial for post CABG patients.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
42

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • Pakistan
    • Punjab Province
      • Sialkot, Punjab Province, Pakistan, 40100
        • Recruiting
        • Imran Idrees teaching hospital sialkot
        • Contact:
        • Principal Investigator:
          • Nida Khalid, MS PT

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Both genders (male, female)

    • Patient who underwent a successful CABG (no complications during surgery and/or in the following weeks)
    • Patients willing to participate in the phase II cardiac rehabilitation program.
    • Age between 30 to 60 years
    • Patients having no impairment in the musculoskeletal system

Exclusion Criteria:

  • Patients with unstable congestive heart failure and symptoms of significant myocardial ischemia, including chest pain

    • Patients with uncontrolled diabetes mellitus or hypertension.
    • Patients with any motor or neurological impairment
    • Patients with severe disturbance of consciousness, having an orthopedic problem and critical limb ischemia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: aerobic exercise
Aerobic exercise refers to the type of repetitive, structured physical activity that requires the body's metabolic system to use oxygen to produce energy. Aerobic exercise improves the capacity of the cardiovascular system to uptake and transport oxygen. Aerobic exercise training intensity is the most important variable in improving CRF during CR for most patients. Upper limb cycle ergometry is a form of aerobic exercise that can be tailored to individual needs. In the described protocol, patients perform 5 minutes of active exercise followed by 2 minutes of recovery, maintaining 20-30 rotations per minute. Moderate-intensity continuous aerobic training (MCT) is defined as 60% to 85% of peak heart rate and/or RPE of 12 to 14 on the 6 to 20 scale.
Behavioral: aerobic exercise

Aerobic Exercise Plan:

  1. Warm-up (5 minutes): - Light arm movements (e.g., arm circles, shoulder rolls) - Dynamic stretching (e.g., arm swings)
  2. Aerobic Exercise (20-30 minutes): - Arm cycle ergometer - Intensity: Moderate (40-60% of maximum heart rate reserve) - Frequency: 2-3 times per week
  3. Cool-down (5-10 minutes): - Static stretching (e.g., bicep, triceps, chest muscles)
Active Comparator: Aerobic Exercise and strength training
supervised exercise sessions 3 times per week for 6 months. Thus, in addition to the aerobic exercise training (as above), upper extremity resistance exercise was initially prescribed at 30% of 1RM, increasing to a maximum of 70% of 1RM by 4 weeks. Seventy percent of 1RM is in the comfortably hard range (5-7 on the Borg 1-10 scale, which is comparable to 13-15 on the 6-20 Borg scale). Each exercise repetition involved a slow controlled movement with approximately 2 sec of concentric lifting and 4 sec of eccentric lowering. Proper breathing techniques were enforced (with expiration during concentric lifting and inspiration during eccentric lowering).
Behavioral: Aerobic Exercise and strength training
  1. Warm-up (5-10 minutes): - Light cardio (e.g., walking, jogging in place) - Dynamic stretching (e.g., arm circles, leg swings)
  2. Aerobic Exercise (10-20 minutes): - Arm cycle ergometer - Intensity: Moderate (40-60% of maximum heart rate reserve) - Frequency: 2-3 times per week
  3. Resistance Training (10-15 minutes): - Upper extremity exercises using resistance bands or light dumbbells - 2-3 sets of 8-12 repetitions per exercise - Intensity: 30-70% of 1RM - Frequency: 2-3 times per week

Cool-down (5-10 minutes): - Static stretching (e.g., bicep, triceps, chest muscles)

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Six-Minute Walk Test (6MWT)
Time Frame: 5 weeks
The six-minute walk test (6MWT) is a simple test that objectively evaluates a patient's functional capacity. This simple walk test is particularly applicable in the CAD population due to the risk of acute cardiac events associated with the gold standard maximal exercise testing for assessing functional capacity. The 6MWT requires a 30-m, flat, hard walking path, a stopwatch, a lap counter and two cones to mark the turning points. The patients were instructed to walk as far as possible along the pathway, in 6 minutes. During the test encouragement was not given and only asked about their conditions. At the end, total walked distance was measured and recorded
5 weeks
Step test
Time Frame: 5 weeks
The 6 min step test is a safe, valid, sensitive, and reproducible tool for evaluating cardiorespiratory fitness. The 6MST was shown to be a safe and reliable field test to assess exercise tolerance in a sample of very deconditioned adults at risk of CVD
5 weeks
Vo2 max
Time Frame: 5 weeks
Vo2 max was estimated using a graded exercise test. Oxygen consumption was measured using metabolic gas analyzer. In this research VO2 Max will be measured through a submaximal 6 mint walk test
5 weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
SF-12 Questionnaire
Time Frame: 5 weeks
The SF-12 are multi-item generic health surveys intended to measure general health. The SF 12 is a shorter version of the SF-36 and uses only 12 questions to measure functional health and well-being from the patient's perspective. SF-12 were first published in 1992 and 1996, respectively, with the revised versions of both questionnaires published in 2000. SF-12 measure 8 health domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The SF-12 consists of 12 items: 2 items on physical functioning, 2 items on role physical, 1 item on bodily pain, 1 item on general health, 1 item on vitality, 1 item on social functioning, 2 items on role emotional, and 2 items on mental health.
5 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Riphah International University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Arjumand Bano, MS, Riphah International University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
June 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
August 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 1, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 17, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 20, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 20, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 17, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • REC/RCR & AHS/25/0301

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings